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Abstract  
Bone tissue engineering has combined bespoke scaffolds and osteo-inductive factors to maintain 
functional osteoprogenitors cells. Periosteal osteoblasts have been confirmed as a suitable 
osteoblast source for bone tissue engineering. Suitable matrices have been identified to support 
cell proliferation and differentiation: Demineralised Bone Matrix (DBM), a compatible and 
osteoinductive matrix, and Acellular Human Dermis (AHD), which supports fibroblasts 
proliferation. This study evaluated the osteogenic potential of an Osteogenic Unit (OU), 
developed by combining periosteum, DBM and AHD, in a rodent model of critical size cranial 
defect. Briefly, remnants from the superior maxillary periosteum were used to harvest cells, 
which were characterised by flow cytometry and RT-PCR. Cells were cultures into the OU and 
assessed for viability before implanting these constructs in rodent models. These were compared 
to the control group after three months.  Histological analysis by Hematoxylin-Eosin (H&E), 
Von Kossa and immunostainings, confirmed viable cells positive for CD90, CD73, CD166, 
Runx-2, OPN and Col-I in the OU group, while the control group presented connective tissue 
joined bone edges of injury zone. We can conclude that OU constructs have osteogenic and 
regenerative potential to be used in bone tissue engineering. 
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Introduction 
The accidents and traumas impact on populations’ health is significant in many 
countries. Worldwide annually approximately 1.2 million people die by accidents. In Mexico, 
this is the third cause for mortality in adults and the first in children. One of the main traumas 
with permanent disability risk is the cranial trauma, which needs long-term hospitalisation for 
treatment and still results on long-lasting complications.1-4  
Traditionally, bone lesions caused by cranial trauma are treated with autologous bone 
grafts, which are used by surgeons to restore the shape and function on the skull. However, 
long-term follow up of these patients shows that such cranial reconstructions are compromised 
by graft reabsorption. In addition to the soft tissue prolapse, the rapid migration of fibroblasts 
into the bone defect has been identified as an obstacle for osteo-regeneration. This has been 
overcome by using a “guided bone regeneration” technique, which uses membranes designed to 
act as a barrier to stop the prolapse of the adjacent soft tissue, as well as fibroblast infiltration.5  
Cranial reconstruction continues to be a challenge not fully addressed by current conventional 
treatments, as these cannot restore loss bone tissue. Bone tissue engineering offers an alternative 
to regenerate cranial defects by using an extracellular matrix (either synthetic or natural), 
bioactive molecules (growth and differentiation factors), and cells to regenerate the damaged 
tissue.6    
 Not all human cells present good proliferation and differentiation potential in vivo 
and/or in vitro. One of the suitable cells for bone tissue engineering are mesenchymal stem cells 
(MSC), which can be found on adult tissues such as bone marrow, adipose tissue, blood, and 
periosteum, and can retain the ability to differentiate into specific lineages.7  The periosteum is a 
connective tissue membrane, micro-vascularised, that covers the external surface of bone. This 
is formed by two layers, the external with fibroblasts and Sharpey fibres, and the internal, with 
mesenchymal stem cells and osteoprogenitors to support normal bone growth, repair and 
regeneration. Hence, periosteal mixed populations include fibroblasts, osteoblasts, MSCs and 
pericytes. The periosteum plays an essential role in bone development and repair. Applications 
could also be therapeutic in craniofacial bone regeneration.7-9  
Previous works show that periosteal cells can differentiate into bone and cartilage.10 Periosteal 
tissue grafting has demonstrated successful results in bone regeneration. The regeneration of an 
engineered, functional periosteum-like tissue could aid in bone regenerative therapies.11 An 
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advantage of harvesting periosteum for clinical applications, including cleft palate surgery, is 
that this can be obtained from the oral cavity with minimum morbidity at the donor site.12  
Tissue engineering requires scaffolds that mimic the biological cues for induction and 
development of Neotissue.6 Several research groups have demonstrated potential bone 
substitutes suitable for clinical use. This ideal substitute needs to be cheap, readily available, 
easy to handle, radiotransparent, biocompatible, osteo-inductor (able to induce differentiation of 
stem cells into osteoblasts) and osteo-conductive (bone growth from existing bone tissue).13  
Non-re-absorbable materials used previously for cranial reconstruction, such as acrylics, metals 
and ceramics, have been associated with complications including skin rupture, graft exposure, 
extrusion and infection.14 Paediatric patients have the additional disadvantage that such grafts 
need to be replaced to match their ongoing growth rate.  
An alternative to these materials is a Demineralised Bone Matrix (DBM), which is 
biocompatible and osteoinductive. Several studies have reported that after DBM implantation 
on cranial defects, local MSCs proliferate and differentiate into cartilage and then into neo-
bone.15,16  
Furthermore, results with Acellular Human Dermis (AHD) for cranial reconstruction 
demonstrated to support homing of fibroblasts and their proliferation, as well as rapid 
neovascularisation.  This AHD, from cadaveric human skin, is formed by collagen type IV and 
type VII, elastin and laminin.15,17  
This team has worked previously developing biological substitutes for tissue regeneration and 
repair, focusing on critical size-cranial defects, confirming the potential of an Osteogenic Unit 
(OU) formed by AHD, DBM and bone-marrow MSCs. This graft retains osteoconductive, 
osteoinductive and osteogenic properties for neobone. The periosteum is a suitable source of 
MSCs with osteogenic potential and minimal morbidity when harvesting them. The objective of 
this study is to assess new bone tissue formation when combining the OU and periosteal cells in 
a preclinical model of athymic mice with bone cranial defects. 
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Materials and Methods 
Cellular Isolation and Culture 
Biopsies were taken from surgery remnants from cleft palate procedures in paediatric patients. 
The periosteum remnant was from the anterior region of the superior maxilla. The group 
included samples from seven paediatric patients, whose parents granted permission for its use 
for research. Periosteal biopsies of  0.3 x 0.3 cm (approximately) were incubated in 
DMEM/F12 (Gibco®, USA) with penicillin-streptomycin and amphotericin B (Gibco®, 
USA), and transported at 2° a 4°C from the surgical theatre to the research unit at the 
National Institute of Rehabilitation. Biopsies were then cut into two similar squares of 
0.15 cm x 0.15 cm and then placed in Petri dishes (BD Falcon, USA). Cells were 
cultures in DMEM-F12 with 10% of Fetal Bovine Serum (FBS, Gibco®, USA), 
supplemented with penicillin-streptomycin and amphotericin B (Gibco®, USA), and 
incubated at 37°C, 5% of CO2. Media was replenished two/three times a week until 
confluence.  
 
Cellular Viability 
Prior to the OU implant into the in vivo models, cell viability was verified by seeding 5x104 
cells and incubating with LIVE/DEAD  kit (Invitrogen, Carlsbad, CA, USA) before visualising 
by inverted fluorescent microscope (Carl Zeiss Micro-Imaging, Thornwood, NY). 
 
Immunophenotypic characterisation 
Flow cytometry (FACSCalibur®) was used to characterise samples of 250 000 cells labelled 
with monoclonal antibodies for hematopoietic cell markers [anti-CD14-APC (BD Pharmigen 
TM), anti-CD34-APC (BD Pharmigen TM), anti-CD45-FITC (BD Pharmigen TM)] and MSCs 
markers [anti-CD73-PE (BD Pharmigen TM), anti-CD90-FITC (BD25 Pharmigen TM), anti-
CD166 (Santa Cruz Biotechnology, Inc.)]. Results were used to determine the percentage of 
MSC in the periosteum using Cell Quest PRO ™ (Becton Dickinson).  
 
RNA Extraction and RT(Reverse Retrotranscriptase-)-PCR  
In order to confirm the osteogenic potential of periosteum cells, RNA was extracted from 
confluent cells prior to implant. Briefly, RNA was extracted using TRIZOL® (Invitrogen, CA, 
USA), following the supplier’s protocol. Total RNA was dissolved in 30 µL of DEPC 
(Diethylpyrocarbonate, Sigma-Aldrich) water and stored at -80°C until analysis. RNA 
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concentration was determined using a spectrophotometer GeneQuant pro (Amersham 
Biosciences)®. Reverse transcription was used to obtain cDNA from 1µg of total RNA total by 
using the 1st Strand cDNA Synthesis Kit for RT-PCR (AMV)® (Roche Applied Science).  The 
PCR was conducted in a thermocycler (Eppendorf Ag, Master cycler gradient), with a final 
volume of 20μl of reaction. Osteogenic markers included Runx-2, Osteopontin (OPN) y 
Collagen type I (Col-I) and were normalised to the housekeeping gene GAPDH 
(glyceraldehydo-3-Fosfatase-deshidrogenase). Full temperature sets and primer sequences are 
shown in table 1. Gels were visualised in an Aplhamager Gel Documentation (Alpha 
Innotech®). 
In vivo Model   
All animals were treated in accordance with Public Health Service Policy on Humane Care and 
Use of Laboratory Animals (August 2002), implemented by the Office of Laboratory Animal 
Welfare, Harvard Medical School IACUC. Cells were harvested at 80% confluence and seeded 
at 5x104 cells into BDM and later onto AHD, forming the OU for the in vivo model.  Five 
weeks old athymic mice nu/nu, with a 5mm2 (critical size) cranial defects, was used to evaluate 
the implant of the OU; this procedure was carried out in the bioterium operating room under 
sterility conditions, in the immunocompromised animals unit at the National Rehabilitation 
Institute. After three months, mice were euthanized for a craniotomy to remove the regenerated 
area, which was fixed in 4% PFA (Paraformaldehyde) until analysis. 
 
Histological and Immunohistochemistry Analysis  
Fixed craniotomy samples were dehydrated and transferred to xylene for paraffin embedding. 
These samples were sectioned at 5µm. Slides were stained in Hematoxylin and Eosin (H&E). 
Immunohistochemistry analysis was done for Col-I (1:50; anti-goat polyclonal antibody, Santa 
Cruz, Santa Cruz, CA), Runx-2 (1:50; anti-goat polyclonal antibody, Santa Cruz, Santa Cruz, 
CA), Alkaline Phosphatase (1:50; anti-rabbit polyclonal antibody, Santa Cruz, Santa Cruz, CA) 
and Osteopontin (1:50; anti-goat polyclonal antibody, Santa Cruz, Santa Cruz, CA). Secondary 
antibodies from ABC Elite VECTASTAIN kit (Vector Laboratories) were diluted 1:100 and 
visualised with Liquid DAB+ kit (Dako Cytomation) and Hematoxylin. Samples were gelatine-
coated and analysed under the microscope (Axio-observer, Karl-Zeiss). For bone formation, 
Von Kossa staining was used by incubating the samples with 1% silver nitrate and UV light for 
1 hour. These were washed and incubated with 5% sodium thiosulphate for 5 minutes before 
staining with rapid red. 
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Results 
Periosteal Cells from the biopsied superior maxilla remained viable and expressed osteo-
markers in vitro 
Cell viability was assessed by fluorescent microscopy using calcein, according to the 
supplier’s information. This showed viable cells onto the OU, as can be seen in Figure 1. 
The gene expression analysis of the periosteal cells was confirmed by Runx-2, OPN and 
Col-I, in addition to GADPH, the housekeeping gene. After four weeks of cell culture, Runx-2, 
OPN and Col-I remained expressed in all samples cultured in vitro. This confirms periosteal 
cells preserved their osteogenic potential (Fig 1B) prior to implantation. 
 
Periosteal Cells from the biopsied superior maxilla expressed markers for MSCs 
In order to assess the percentage of the MSCs population from the periosteum biopsy 
and their differentiation potential, cell phenotype was analysed using flow cytometry. Results 
show that 92.87% were positive for CD90 (fig. 1C), 48.91% for CD73 (fig. 1D), and 2.38% for 
CD166 (fig. 1E). Hematopoietic markers were also analysed, CD34 (fig. 1F), CD45 (fig. 1G), 
and CD14 (Fig. 1H), expressed in 2.15%, 0.82% y 0.27%, respectively, as can be seen in Figure 
1.  
Periosteal Cells from the biopsied superior maxilla seeded onto the Osteogenic Unit 
preserved their phenotype.  
The osteogenic potential of the OU in the animal models were analysed by H&E, which 
confirmed that the OU supported formation of neo-tissue in vivo, this was structurally similar to 
bone (Fig 2a). Bone trabeculae and hematopoietic cells were present at the periphery, with 
osteoblasts at the centre forming immature bone, and osteoprogenitor cells in between the 
periphery and centre. The control group with no OU implant only showed connective tissue 
joining the boundaries of the cranial defect but no neo-tissue (Fig 2a). 
Immunohistochemical analysis of the explanted neo-tissue was performed to evaluate 
the formation of de novo bone in the neo-tissue. This was positive for OPN (fig. 2b), Col-I (fig. 
2c), Runx-2 (fi. 2d) and FA (fig. 2e), all of them characteristic proteins of bone metabolism. 
Mineralisation was confirmed by Von Kossa, which shows dark calcium deposits as can be seen 
in Fig 2f. 
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Discussion 
Periosteal tissue grafting has demonstrated successful results in bone regeneration; the 
presence of a functional periosteum accelerates healing in bone defects by providing a source of 
progenitor cells that aid in repair.11 In 1742, Duhamel studied the osteogenic potential of 
periosteum. Ollier showed the role played by the periosteum in bone regeneration,18  while Fell 
was the first to successfully culture periosteum and concluded that this tissue might have the 
capability to form mineralized tissue in vitro.19 Several teams have confirmed periosteal cells’ 
ability to promote bone tissue formation and the relatively easy harvesting from the oral cavity, 
minimising morbidity.20,12  This study proves that periosteal cells from cleft palate surgery can 
be harvested and expanded in vitro.  We propose that non-invasive surgery could be performed 
to obtain periosteal cells as an autologous treatment for patients with bone defects, such as cleft 
palate or cranial defects. This could be particularly useful in paediatric cases where standard 
implants need to be replaced as the patient continues to grow. The method we use to perform 
this study could be successful, because the first place the AHD serves as a barrier and allows us 
to preserve the integrity of the mass of the brain without compromising the risk of infiltration, it 
is for this reason that has not been used cells directly over the lesion so that they were not in 
direct contact with the brain mass. We propose that the AHD served us as a barrier and material 
support (scaffold) for the combination of demineralized bone cells, ensuring that bone formation 
does not invade the brain mass and not cause any damage. 
The study confirmed that periosteal cells preserved their osteogenic potential not only in 
in vitro monolayer culture but more importantly, when culture into the OU and implanted into 
animal models, promoting de novo bone formation. 
As described previously, the periosteal cells are a mixed population that include 
fibroblasts, MSCs and periocytes. The MSCs cells have been confirmed by the presence of 
surface markers for CD9, CD90, CD73, CD105, CD166, but negative for CD34 and CD45.7 
Pittenger and Dominici defined CD29, CD73, CD90 and CD105 are indicative of MSC 
phenotype. MSC do not express the haematopoietic marker CD45 and express the adhesion 
molecules CD166 and CD140b.21,22 Some research suggests that the MSCA-1 (Mesenchymal 
stem cell antigen-1) and CD166 positive have high osteogenic potential compared with MSCA-
1 and CD166 negative.23  Periosteal cells from cleft palate surgery expressed positive markers 
for CD90, CD73, and a reduced CD166; however, expression CD34, CD45, and CD14, were 
considered negative as results were 2.15%, 0.82% and 0.27%, respectively. This confirms a 
limited presence of MSCs in the biopsies. This could be because biopsy cells are of type 
osteogenic, or it could also be that in this fragment size was very small; in the future propose we 
8 
 
to do a study in which evaluate the percentage of MSC in different sizes fragments and compare 
the osteogenic potential of cells CD166 positive.  
Results from RT-PCR suggest that our population is mainly osteoblasts, as we had high 
levels of expression of Runx-2 (essential nuclear proteins for bone morphogenesis), Col-I and 
OPN, all synthesised by osteoblasts. It is possible that the osteogenic phenotype had been 
retained from the in vivo osteo-differentiation signalling prior to the cell harvest, which is also 
supporting the periosteal MSC population into osteo-differentiation.  
Biomaterial properties are keys in tissue engineering both as physical supports for 3D 
cell seeding and proliferation, as well as for bioactive molecules delivery.5 The materials used 
for the OU has not cytoxic effect on periosteal cells, confirmed by viability assays and imaging. 
Hence, this combination of DBM and AHD supports cell adhesion and proliferation, in addition 
to maintain differentiated phenotypes such as the periosteal osteoblasts. This could also promote 
osteodifferentiation in periosteal MSCs. 
Staining with H&E confirmed that de novo bone with similar characteristics to those in 
bone tissue, including trabecular structure, in the in vivo model. However, the control group 
only showed connective tissue joining the edges of the bone defect. Further immunostainings 
with Runx-2, essential for osteoblastic differentiation and bone morphogenesis; OPN, indicating 
high affinity to hydroxyapatite binding; Col-I and AlkPhos, an early marker for osteogenic 
differentiation, were all positive for the OU group. Bone Morphonogenic proteins (BMPs) 
promote Runx-2 transcription, which is directly involved in AlkPhos, OPN and Col-1 gene 
expression.24  Hence, it is possible that the BMPs from the DBM’s could have also contributed 
to retain the osteogenic potential of periosteal cells and its MSCs osteo-differentiation. These 
results indicate that the OU contains viable osteoblasts that can produce collagen matrix and 
synthesis of AlkPhos and OPN when implanted in this animal model. Moreover, bone 
mineralisation confirms successful differentiation in neotissues. The Von Kossa staining 
corroborates the presence of calcium deposits and mineralisation in the OU group. 
Osteoblasts express a high osteogenic potential and bone matrix production, thus, they 
are often used for cell seeding for regenerative therapies.25 Periosteal osteoblasts could offer a 
suitable source with low morbidity if cells are harvested from alveolar bone. This alveolar bone, 
which lines the alveoli in the maxilla, is easy to access from the oral cavity, therefore less 
invasive than bone marrow harvesting. 
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Conclusion 
The study confirms that remaining tissue from cleft palate or lip correction surgery can 
be cultured and expanded in vitro before combining them with biomaterials such as DBM-
AHD, and still preserve its bone regenerative potential. This OU, formed by periosteal cells, 
DBM and ADH, not only preserved its cellular function, but also promoted bone regeneration 
and mineralisation, collagen matrix formation and AlkPhos synthesis, in defects of critical size. 
Hence, further work is needed in order to quantify osteoblasts/MSCs populations, and to 
establish the efficiency of the MSCs’ osteo-differentiation, before this can be used as a clinical 
therapy for de novo bone graft for critical size maxillofacial defects or cleft palate. 
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Table Legends 
Table 1. The Primers sequences and temperature used for RT-PCR.  
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Figures Legends 
 
 
Figure 1. Cell Viability and Osteogenic Phenotype (A) Cell Viability assessed by 
Live/Dead assay showing homogeneous distribution of live cells on the Osteogenic Unit 
(OU) (B) Gene expression of Runx-2, OPN and Col-I after 2-4 weeks in all seven 
samples. (C-G). Flow Cytometry Analysis of periosteal cells expressing: (C) 92.87% of 
CD90, (D) 48.91% of CD73, (E) 2.38% of CD166  and for hematopoietic markers (F) 
2.15% of CD34, (G) 0.82% of CD45 y (H) 0.27% of CD14. 
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Figures Legends 
 
 
 
Figure 2.  Cells harvested from the biopsy and seeded into the OU retain their 
phenotype and promote bone formation. H&E Staining of de novo tissue (a). This 
shows the tissue from the experimental group implanted with an OU graft of 5mm2 in the 
skull, after three months. New bone tissue was observed, including bone trabeculae, 
osteoprogenitor cells and osteoblasts. The control group only showed connective tissue 
on the borders of the bone defects (b). Immunohistochemistry from the de novo tissue. 
(b-e). Bone markers were positive for (b) OPN, (c) Col-I, (d) Runx-2 and (e) FA, arrows 
in b and d highlight regions with positive markers.  Von Kossa staining of the de novo 
tissue (f). Bone mineralisation is confirmed in the experimental group.  
